JULIE MABRY: Open Payments
NPI 1326650110 · GREENVILLE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$433 in 21 payments from 13 companies in 2025. Trend: 2023 $1,006 · 2024 $1,031 · 2025 $433
Food & beverage: $433
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 3 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $56 |
| Amgen Inc. | 3 | $56 |
| Novo Nordisk Inc | 2 | $52 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $20 |
Products named: IBSRELA, JARDIANCE, TAVNEOS, Ozempic, Wegovy, VELPHORO, LUPKYNIS, Kerendia.
Industry payments across MS — which companies pay providers there.
